Eupraxia Pharmaceuticals
June 16, 2025
Company Presentation
Inflammation
153A
Eupraxia Pharmaceuticals is a late clinical stage company with multiple assets. The focus of this presentation will be to discuss Phase 2 data in Eosinophilic Esophagitis.
Company HQ City:
Victoria
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
2012
Lead Product in Development:
EP104GI for Eosinophilic Esophagitis
CEO
Dr. James Helliwell
Development Phase of Lead Product
Phase II
Exchange
NASDAQ
Ticker
EPRX
When you expect your next catalyst update?
Phase 2 data in Q3 2025
What is your next catalyst (value inflection) update?
Q3 2025
Website
www.eupraxiapharma.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}